SEARCH

SEARCH BY CITATION

References

  • 1
    Engdal S, Klepp O, Nilsen OG. Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther 2009; 8: 2936.
  • 2
    Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab 2008; 9: 10631120.
  • 3
    Werneke U, Earl J, Seydel C, Horn O, Crichton P, Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004; 90: 408413.
  • 4
    Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 2004; 22: 48104815.
  • 5
    Woelkart K, Marth E, Suter A, Schoop R, Raggam RB, Koidl C, Kleinhappl B, Bauer R. Bioavailability and pharmacokinetics of Echinacea purpurea preparations and their interaction with the immune system. Int J Clin Pharmacol Ther 2006; 44: 401408.
  • 6
    Colalto C. Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment. Pharmacol Res 2010; 62: 207227.
  • 7
    Woelkart K, Bauer R. The role of alkamides as an active principle of echinacea. Planta Med 2007; 73: 615623.
  • 8
    Matthias A, Blanchfield JT, Penman KG, Toth I, Lang CS, De Voss JJ, Lehmann RP. Permeability studies of alkylamides and caffeic acid conjugates from echinacea using a Caco-2 cell monolayer model. J Clin Pharm Ther 2004; 29: 713.
  • 9
    Modarai M, Gertsch J, Suter A, Heinrich M, Kortenkamp A. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J Pharm Pharmacol 2007; 59: 567573.
  • 10
    Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007; 100: 2330.
  • 11
    Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY, Alfaro RM, Stevenson JM, Kovacs JA. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010; 30: 797805.
  • 12
    Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75: 89100.
  • 13
    Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76: 428440.
  • 14
    Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187196.
  • 15
    Kuppens IE, van Maanen MJ, Rosing H, Schellens JH, Beijnen JH. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 2005; 19: 355361.
  • 16
    Goey AK, Rosing H, Meijerman I, Sparidans RW, Schellens JH, Beijnen JH. The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 902: 151156.
  • 17
    Goey AK, Sparidans RW, Meijerman I, Rosing H, Schellens JH, Beijnen JH. A sensitive LC-MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 4148.
  • 18
    Goey AKL, Meijerman I, Rosing H, Keessen M, Beijnen JH, Schellens JHM. Abstract 761: phase I interaction study of docetaxel with supplementation of St. John's wort. Cancer Res 2012; 72: (Suppl. 1): 184.
  • 19
    Launay-Iliadis MC, Bruno R, Cosson V, Vergniol JC, Oulid-Aissa D, Marty M, Clavel M, Aapro M, Le Bail N, Iliadis A. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 1995; 37: 4754.
  • 20
    Perry NB, van Klink JW, Burgess EJ, Parmenter GA. Alkamide levels in Echinacea purpurea: a rapid analytical method revealing differences among roots, rhizomes, stems, leaves and flowers. Planta Med 1997; 63: 5862.
  • 21
    Modarai M, Silva E, Suter A, Heinrich M, Kortenkamp A. Safety of Herbal Medicinal Products: echinacea and Selected Alkylamides Do Not Induce CYP3A4 mRNA Expression. Evid Based Complement Alternat Med 2011; 2011: 213021.
  • 22
    Harmsen S, Koster AS, Beijnen JH, Schellens JH, Meijerman I. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. Drug Metab Dispos 2008; 36: 11661171.
  • 23
    Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E, Gan LS. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30: 795804.
  • 24
    Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 2000; 58: 361372.
  • 25
    Teo YL, Saetaew M, Chanthawong S, Yap YS, Chan EC, Ho HK, Chan A. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat 2012; 133: 703711.
  • 26
    Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 36833690.
  • 27
    van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, Bol CJ, de Vries R, Palmer PA, Verweij J. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 2002; 38: 10901099.
  • 28
    van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 2000; 6: 13651371.
  • 29
    Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 2004; 10: 72207228.
  • 30
    Puisset F, Chatelut E, Dalenc F, Busi F, Cresteil T, Azema J, Poublanc M, Hennebelle I, Lafont T, Chevreau C, Roche H. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 2004; 54: 265272.
  • 31
    Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008; 52: 772779.
  • 32
    van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008; 11: 7798.
  • 33
    Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998; 8: 391401.
  • 34
    Van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. Cancer 2003; 98: 18551862.
  • 35
    Brunsvig PF, Andersen A, Aamdal S, Kristensen V, Olsen H. Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy. BMC Cancer 2007; 7: 197.
  • 36
    Modarai M, Yang M, Suter A, Kortenkamp A, Heinrich M. Metabolomic Profiling of Liquid Echinacea Medicinal Products with In Vitro Inhibitory Effects on Cytochrome P450 3A4 (CYP3A4). Planta Med 2009; 76: 378385.